Hard to resist
Article Abstract:
A number of UK biotechnology companies involved in developing drugs have performed well in 1995. They include British Biotech which saw a rise in its share price following encouraging reports of an anti-cancer product. Oxford Molecular and Cortecs have also performed well, as has Chiroscience. Diagnostics companies have performed less consistently with Enviromed seeing a fall in its share price, and Drew Scientific seeing a share price rise but still below its placing price in May 1993.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Pharmaceuticals: catch the merger wave
Article Abstract:
Sandoz and Ciba have agreed to a merger which could have an impact on the pharmaceutical industry as a whole. The merger creates the second biggest drugs company world wide and large companies have a number of advantages in the industry. They have more power to buy technology from biotechnology firms, and enhanced purchasing power which helps at a time of price competition. UK pharmaceutical companies may follow this course, and analysts are assessing which companies will merge.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Pharmaceuticals and healthcare
Article Abstract:
Trends affecting British pharmaceutical and healthcare firms are examined in detail.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Proteus: mad cows to the rescue. Dechra Pharmaceuticals. Dechra reigns cats and dogs
- Abstracts: Corporate reorganizations and non-cash auctions. Market valuation and merger waves. Strategic trading when agents forecast the forecasts of others
- Abstracts: A dynamic petrochemical company. Playing the ratings game. Thais celebrate TPI agreement
- Abstracts: Charitable contributions of depreciated capital assets: AMT may change the conventional planning wisdom. Capitalization of investment advisory fees: can the case be made?
- Abstracts: Hidden stars. All change, please. Industry's metal is put to the test